The research of Donald J. Tindall, Ph.D., and his team focuses on prostate cancer and the mechanisms by which prostate cancer cells survive following androgen ablation, the most common therapy for advanced prostate cancer.
Dr. Tindall's research has been supported by National Institutes of Health grants CA121277, CA91956 and CA125747, and the T.J. Martell Foundation.
Dr. Tindall's laboratory is testing the hypothesis that the androgen receptor plays a key role in androgen-independent prostate cancer following androgen ablation therapy.
In addition, his team is studying the mechanisms by which co-regulatory proteins modulate the transcriptional activity of the androgen receptor and how these proteins are altered in prostate cancer.
Dr. Tindall and his colleagues are also studying the downstream targets of the androgen receptor involved in cell proliferation and cell death by focusing on the molecular mechanisms by which Forkhead transcription factors are regulated by androgens and how this affects proliferation and apoptosis in prostate cancer cells.
Significance to patient care
It is anticipated that this research will identify cellular targets for detection, prognosis, prevention and treatment of prostate cancer.